Mubadala and G42 have launched M42, a healthcare company that seeks to combine its resources and expertise to advance medical research and capabilities in Abu Dhabi. The new entity is the result of a merger between the healthcare units of both companies and aims to provide the highest levels of personalised, precise and preventive care.
M42 will manage a wide portfolio of healthcare assets in the region, including Amana Healthcare, Biogenix Labs, Danat Al Emarat, HealthPoint Hospital, the HealthPlus network of speciality centres, Moorfields Eye Hospital Abu Dhabi, Imperial College London Diabetes Centre, Insights Research Organisation & Solutions, the Omics Centre of Excellence and the National Reference Laboratory, among others.
According to Hasan Al Nowais, Group Chief Executive and Managing Director of M42, the launch of the new company is expected to “impactfully disrupt” the global healthcare industry. M42’s vision is to transform lives through innovation by providing personalised and precise patient care. The company plans to empower dedicated healthcare professionals with the latest technology to optimise patient outcomes.
M42 will also consider opportunities for international expansion and new partnerships. The company intends to collaborate with leading researchers and HealthTech ecosystems and partner with global peers to solve the world’s most pressing healthcare challenges. Abu Dhabi has been working to become a hub for the global healthcare industry and has taken steps such as enacting sweeping health protocols and a vaccine mandate during the COVID-19 pandemic. The Fatima bint Mubarak Centre at Cleveland Clinic Abu Dhabi, which opened last month, provides patients with personalised care, including screening and diagnostic testing, advanced radiation treatments and precision cellular therapies.
